Varicose veins affect roughly one in three adults at some point in their lives. For most of those people, the question isn’t whether to seek treatment — it’s which treatment to seek. And increasingly, that conversation starts with one method sitting firmly at the top of clinical guidance: ultrasound-guided sclerotherapy, or UGS.
Understanding why requires more than a surface-level comparison. It means looking at what the evidence actually shows — success rates, recovery timelines, procedural risks — and understanding how modern phlebology arrived at its current position.
This is that comparison.
For much of the twentieth century, surgical stripping was the default intervention for symptomatic varicose veins. The procedure involves ligation of the saphenofemoral or saphenopopliteal junction, followed by physical removal of the great or small saphenous vein through a series of incisions.
It works. In appropriately selected patients, surgical stripping produces saphenous vein abolition in approximately 80 to 85 per cent of cases at five-year follow-up. Symptom relief rates are comparable, and for many years this was considered the benchmark.
But the costs are significant.
The procedure requires general or regional anaesthesia. Post-operative recovery typically spans two to four weeks, with patients advised to avoid strenuous activity for the full duration. Wound complications — including haematoma, infection, and nerve injury — occur in a meaningful proportion of cases. Saphenous nerve injury, which produces numbness or paraesthesia along the medial calf, is reported in up to 40 per cent of patients undergoing below-knee stripping. Wound infection rates sit at around three to five per cent, and haematoma formation is documented in up to seven per cent of cases.
There is also the matter of recurrence. Long-term studies — including the landmark REACTIV trial — have demonstrated that surgical recurrence rates at ten years can reach 25 to 30 per cent, driven largely by neovascularisation at the ligation site.
Ultrasound-guided sclerotherapy uses real-time duplex imaging to deliver a sclerosant agent — typically polidocanol or sodium tetradecyl sulphate in foam form — directly into the target vein. The chemical disrupts the vessel’s endothelial lining, triggering fibrosis and permanent closure. No incisions. No anaesthesia. No hospitalisation.
Over the last two decades, clinical evidence to support UGS has matured. Truncal varicosities have been reported to have technical success rates of 85 to 95 percent in pooled data from controlled trials, defined as confirmed venous closure on duplex at twelve weeks. Cumulative success rates improve further when combined with targeted sessions for residual vessels.
Recovery is where the contrast becomes most pronounced. Patients undergoing UGS typically return to normal daily activity within 24 to 48 hours. Compression hosiery is worn for five to seven days post-procedure. There is no wound to manage, no sutures to remove, and no requirement for general anaesthesia — which itself carries non-trivial perioperative risk, particularly in older or medically complex patients.
The shift in clinical preference is not simply a matter of patient convenience. It reflects a body of evidence that has accumulated to the point where major bodies have revised their formal positions.
The UK’s National Institute for Health and Care Excellence — NICE — updated its guidance on varicose veins in 2013 and has maintained this position in subsequent reviews. NICE recommends endothermal ablation — laser or radiofrequency — as first-line treatment where suitable, with ultrasound-guided foam sclerotherapy as the recommended second-line option. Surgical intervention is positioned as a last resort, recommended only when minimally invasive techniques are contraindicated or have failed.
This is corroborated by the European Society for Vascular Surgery. Thermal ablation and sclerotherapy are the preferred treatment options in clinical practice guidelines because they are as effective or more effective than surgery but with far less risk to the patient and a faster recovery.
The Australian College of Phlebology also advocates the use of non surgical modalities as first line therapy, with surgical stripping reserved for those cases where the anatomy or vessel characteristics make catheter-based or injection techniques impossible.
Historically, one of the criticisms levelled at sclerotherapy has been its long-term durability. Early liquid sclerotherapy without imaging guidance was associated with variable results and a relatively high rate of recanalization. That changed with ultrasound guided foam sclerotherapy.
Comparative data at five years suggest that UGS with appropriate technique and adequate follow-up achieves broadly similar recurrence rates to surgery. The REACTIV and RABIT trials, which directly compared surgery with sclerotherapy, found no statistically significant difference in quality-of-life outcomes at five years, although surgery resulted in marginally better freedom from varicosities in selected cases of complex truncal disease.
The key variable is the operator. UGS outcomes are strongly influenced by procedural precision — accurate placement under duplex guidance, appropriate foam concentration, and correct patient positioning. In the hands of an experienced phlebologist, the recurrence rates for UGS are clinically comparable to surgery, without the associated procedural burden.
Neither approach is without risk. Objective transparency requires stating both clearly.
Surgical stripping carries the following documented risks:
UGS carries its own risk profile:
The argument for minimally invasive approaches is not based on one study or one guideline. It’s the cumulative weight of evidence going one way: equivalent long-term outcomes, much lower procedural risk and a recovery burden that patients can reasonably manage without disrupting work or family life.
Surgery still plays a role. Surgical treatment is still indicated in some anatomical situations, with vessel diameters unsuitable for foam techniques or in case of recurrence after previous endovenous procedures. Phlebology is not a one-size-fits-all discipline.
But the default has changed. Most patients presenting with symptomatic truncal varicosities today 2014 particularly great saphenous vein incompetence 2014 are candidates for non-surgical management. The question worth asking is not: can this be treated surgically? It is: why would we operate when the evidence supports a safer alternative with comparable results?
That shift in framing is what defines modern phlebology.
Most clinical metrics don’t strongly favour surgical stripping over UGS. The evidence supports non-surgical intervention as the primary line of treatment for the majority of varicose vein patients. Not because it’s newer, but because it consistently demonstrates acceptable efficacy with a substantially more favourable risk and recovery profile.
Clinical reality of contemporary UGS is success rates of 85 to 95 per cent at twelve weeks, return to normal activity within 48 hours, no general anaesthesia and a documented safety record over large patient populations.
Surgery has its role. But it is no longer the starting point.
And understanding that distinction — clearly, technically, honestly — is what allows patients and clinicians to make decisions grounded in evidence rather than habit.
Now located at:
43 Glen Osmond Road
Eastwood SA 5063
